US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Scribe Therapeutics / Equity Capital Markets

<ul>
<li>CRISPR platform targets common cardiometabolic diseases, with lead candidate STX-1150 advancing into human trials for durable LDL cholesterol reduction.</li>
<li>Strategic partnerships with Eli Lilly and Sanofi, plus backing from Andreessen Horowitz and other top investors, strengthen the company's credibility and funding profile.</li>
<li>Favorable biotech market momentum and a differentiated platform position Scribe as a closely watched IPO candidate with potential for strong investor demand.</li>
</ul>


CRISPR platform targets common cardiometabolic diseases, with lead candidate STX-1150 advancing into human trials for durable LDL cholesterol reduction.
Strategic partnerships with Eli Lilly and Sanofi, plus backing from Andreessen Horowitz and other top investors, strengthen the company's credibility and funding profile.
Favorable biotech market momentum and a differentiated platform position Scribe as a closely watched IPO candidate with potential for strong investor demand.


Scribe Therapeutics Inc. (SCTX): Peeking at the IPO Prospectus of a Biotech Using CRISPR Technology

<ul>
<li>Late-Stage biotech with a pending FDA review for Oxnimbi, a potential first oral therapy for obstructive sleep apnea.</li>
<li>Phase 3 success and NDA submission reduce development risk relative to earlier-stage biotech IPOs.</li>
<li>IPO is reportedly multiple-times oversubscribed, with strong support from healthcare specialists and crossover institutional investors.</li>
</ul>


Late-Stage biotech with a pending FDA review for Oxnimbi, a potential first oral therapy for obstructive sleep apnea.
Phase 3 success and NDA submission reduce development risk relative to earlier-stage biotech IPOs.
IPO is reportedly multiple-times oversubscribed, with strong support from healthcare specialists and crossover institutional investors.


Apnimed Inc. (APMD): "Waking Up" To the Next Late-Stage Biotech Story

United States

Scribe Therapeutics Inc. is a clinical-stage biotechnology company. The Company develops CRISPR-based genetic medicines for the treatment of cardiovascular and metabolic diseases. Scribe Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Scribe Therapeutics (SCTX US)

Scribe Therapeutics Inc. (SCTX): Peeking at the IPO Prospectus of a Biotech Using CRISPR Technology

CRISPR company Scribe targets cardiometabolic diseases with lead candidate advancing to human trials for LDL cholesterol reduction, backed by...

IPO Boutique

Apnimed Inc. (APMD): "Waking Up" To the Next Late-Stage Biotech Story

Late-stage biotech company set for FDA review of potential first oral therapy for obstructive sleep apnea, IPO oversubscribed with reduced...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Scribe Therapeutics Inc. (SCTX): Peeking at the IPO Prospectus of a Biotech Using CRISPR Technology

​CRISPR company Scribe targets cardiometabolic diseases with lead candidate advancing to human trials for LDL cholesterol reduction, backed by...

IPO Boutique

Apnimed Inc. (APMD): "Waking Up" To the Next Late-Stage Biotech Story

​Late-stage biotech company set for FDA review of potential first oral therapy for obstructive sleep apnea, IPO oversubscribed with reduced...

IPO Boutique

CRISPR company Scribe targets cardiometabolic diseases with lead candidate advancing to human trials for LDL cholesterol reduction, backed by...

Late-stage biotech company set for FDA review of potential first oral therapy for obstructive sleep apnea, IPO oversubscribed with reduced...